Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
After finishing at $23.9 in the prior trading day, Pacira BioSciences Inc (NASDAQ: PCRX) closed at $23.25, down -2.72%. In other words, the price has decreased by -$2.72 from its previous closing price. On the day, 0.82 million shares were traded. PCRX stock price reached its highest trading level at $24.36 during the session, while it also had its lowest trading level at $23.155.
Ratios:
Our goal is to gain a better understanding of PCRX by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.18 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 6.75. For the most recent quarter (mrq), Quick Ratio is recorded 1.99 and its Current Ratio is at 2.41. In the meantime, Its Debt-to-Equity ratio is 0.80 whereas as Long-Term Debt/Eq ratio is at 0.53.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Truist on January 30, 2025, Upgraded its rating to Hold and sets its target price to $25 from $8 previously.
On August 13, 2024, Truist Downgraded its rating to Sell which previously was Buy and also lowered its target price recommendation from $30 to $8.
RBC Capital Mkts Downgraded its Outperform to Sector Perform on August 12, 2024, whereas the target price for the stock was revised from $37 to $14.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 04 ’25 when RIKER LAUREN sold 5,578 shares for $26.21 per share. The transaction valued at 146,208 led to the insider holds 59,564 shares of the business.
WILLIAMS KRISTEN sold 14,376 shares of PCRX for $377,226 on Jun 04 ’25. The Chief Administrative Officer now owns 161,574 shares after completing the transaction at $26.24 per share. On Jun 04 ’25, another insider, RIKER LAUREN, who serves as the Officer of the company, bought 5,579 shares for $26.21 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PCRX now has a Market Capitalization of 1076584320 and an Enterprise Value of 1249514496. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.53 while its Price-to-Book (P/B) ratio in mrq is 1.35. Its current Enterprise Value per Revenue stands at 1.778 whereas that against EBITDA is 7.273.
Stock Price History:
The Beta on a monthly basis for PCRX is 0.49, which has changed by 0.07340717 over the last 52 weeks, in comparison to a change of 0.11937654 over the same period for the S&P500. Over the past 52 weeks, PCRX has reached a high of $29.33, while it has fallen to a 52-week low of $11.16. The 50-Day Moving Average of the stock is -8.28%, while the 200-Day Moving Average is calculated to be 7.39%.
Shares Statistics:
The stock has traded on average 813.92K shares per day over the past 3-months and 554170 shares per day over the last 10 days, according to various share statistics. A total of 46.28M shares are outstanding, with a floating share count of 44.25M. Insiders hold about 4.43% of the company’s shares, while institutions hold 111.26% stake in the company. Shares short for PCRX as of 1749772800 were 5599189 with a Short Ratio of 6.88, compared to 1747267200 on 5679155. Therefore, it implies a Short% of Shares Outstanding of 5599189 and a Short% of Float of 17.119999999999997.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
